Akebia Therapeutics Inc (NASDAQ:AKBA)
| 0.455 BATS BZX Real-Time Price As of 1:36pm ET |  -0.001 / -0.22%Today’s Change | 0.30 Today|||52-Week Range 3.63 | -79.87% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $71.4M |
Company Description
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Contact Information
Akebia Therapeutics, Inc. 245 First Street Cambridge Massachusetts 02142 |
Employees
Shareholders
| Individual stakeholders | 7.46% |
| Mutual fund holders | 26.64% |
| Other institutional | 19.28% |
Top Executives
| John P. Butler | President, Chief Executive Officer & Director |
| Michel Dahan | Chief Operating Officer & Senior Vice President |
| David A. Spellman | Chief Financial Officer, Treasurer & Senior VP |
| Steven K. Burke | Chief Medical Officer & Senior Vice President |
| Michael Rabinowitz | Vice President-Research |
